Oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer aged at least 75 years: A post-hoc subgroup analysis of three phase ii trials

Gerardo Rosati, Stefano Cordio, Giorgio Reggiardo, Giuseppe Aprile, Alfredo Butera, Antonio Avallone, Aniello Tucci, Giuseppe Novello, Giuseppina Blanco, Giuseppe Caputo, Domenico Bilancia, Roberto Bordonaro

Research output: Contribution to journalArticle

Abstract

Patients older than 75 years of age are usually excluded from metastatic colorectal cancer studies based on a combination chemotherapy containing oxaliplatin. Our group conducted three phase II trials in elderly patients in recent years. A post-hoc subgroup analysis of 67 patients aged at least 75 years was included in this study. Oxaliplatin was combined with capecitabine in two trials and with uracil-tegafur (UFT) plus folinic acid in the third trial. In one study, bevacizumab was also added to chemotherapy. The median age of patients was 77 years, and all had a good performance status (0 to 1). The observed overall response rate was 45%, comparable to younger patients (51%, p = 0.49). The estimated median progression-free survival (PFS) time and overall survival (OS) time were 8.7 and 19.3 months, respectively. These results did not significantly differ from those in younger patients (8.0 months for PFS (p = 0.58) and 19.7 months for OS (p = 0.94), respectively). The most common grade 3–4 adverse events included diarrhea (13%), fatigue (13%), peripheral neuropathy (10%), and neutropenia (7%). Moreover, the toxicity was never statistically different from that in younger patients. The efficacy of oxaliplatin-based combination was maintained in fit elderly patients ≥75 years.

Original languageEnglish
Article number578
JournalCancers
Volume11
Issue number4
DOIs
Publication statusPublished - Apr 1 2019

Fingerprint

oxaliplatin
Colorectal Neoplasms
Drug Therapy
Disease-Free Survival
Tegafur
Survival
Uracil
Leucovorin
Peripheral Nervous System Diseases
Combination Drug Therapy
Neutropenia

Keywords

  • Colorectal cancer
  • Doublet chemotherapy
  • Elderly patients
  • Oxaliplatin

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer aged at least 75 years : A post-hoc subgroup analysis of three phase ii trials. / Rosati, Gerardo; Cordio, Stefano; Reggiardo, Giorgio; Aprile, Giuseppe; Butera, Alfredo; Avallone, Antonio; Tucci, Aniello; Novello, Giuseppe; Blanco, Giuseppina; Caputo, Giuseppe; Bilancia, Domenico; Bordonaro, Roberto.

In: Cancers, Vol. 11, No. 4, 578, 01.04.2019.

Research output: Contribution to journalArticle

Rosati, G, Cordio, S, Reggiardo, G, Aprile, G, Butera, A, Avallone, A, Tucci, A, Novello, G, Blanco, G, Caputo, G, Bilancia, D & Bordonaro, R 2019, 'Oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer aged at least 75 years: A post-hoc subgroup analysis of three phase ii trials', Cancers, vol. 11, no. 4, 578. https://doi.org/10.3390/cancers11040578
Rosati, Gerardo ; Cordio, Stefano ; Reggiardo, Giorgio ; Aprile, Giuseppe ; Butera, Alfredo ; Avallone, Antonio ; Tucci, Aniello ; Novello, Giuseppe ; Blanco, Giuseppina ; Caputo, Giuseppe ; Bilancia, Domenico ; Bordonaro, Roberto. / Oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer aged at least 75 years : A post-hoc subgroup analysis of three phase ii trials. In: Cancers. 2019 ; Vol. 11, No. 4.
@article{c64395edd5df4dbfb85c17f3eff889c2,
title = "Oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer aged at least 75 years: A post-hoc subgroup analysis of three phase ii trials",
abstract = "Patients older than 75 years of age are usually excluded from metastatic colorectal cancer studies based on a combination chemotherapy containing oxaliplatin. Our group conducted three phase II trials in elderly patients in recent years. A post-hoc subgroup analysis of 67 patients aged at least 75 years was included in this study. Oxaliplatin was combined with capecitabine in two trials and with uracil-tegafur (UFT) plus folinic acid in the third trial. In one study, bevacizumab was also added to chemotherapy. The median age of patients was 77 years, and all had a good performance status (0 to 1). The observed overall response rate was 45{\%}, comparable to younger patients (51{\%}, p = 0.49). The estimated median progression-free survival (PFS) time and overall survival (OS) time were 8.7 and 19.3 months, respectively. These results did not significantly differ from those in younger patients (8.0 months for PFS (p = 0.58) and 19.7 months for OS (p = 0.94), respectively). The most common grade 3–4 adverse events included diarrhea (13{\%}), fatigue (13{\%}), peripheral neuropathy (10{\%}), and neutropenia (7{\%}). Moreover, the toxicity was never statistically different from that in younger patients. The efficacy of oxaliplatin-based combination was maintained in fit elderly patients ≥75 years.",
keywords = "Colorectal cancer, Doublet chemotherapy, Elderly patients, Oxaliplatin",
author = "Gerardo Rosati and Stefano Cordio and Giorgio Reggiardo and Giuseppe Aprile and Alfredo Butera and Antonio Avallone and Aniello Tucci and Giuseppe Novello and Giuseppina Blanco and Giuseppe Caputo and Domenico Bilancia and Roberto Bordonaro",
year = "2019",
month = "4",
day = "1",
doi = "10.3390/cancers11040578",
language = "English",
volume = "11",
journal = "Cancers",
issn = "2072-6694",
publisher = "MDPI AG",
number = "4",

}

TY - JOUR

T1 - Oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer aged at least 75 years

T2 - A post-hoc subgroup analysis of three phase ii trials

AU - Rosati, Gerardo

AU - Cordio, Stefano

AU - Reggiardo, Giorgio

AU - Aprile, Giuseppe

AU - Butera, Alfredo

AU - Avallone, Antonio

AU - Tucci, Aniello

AU - Novello, Giuseppe

AU - Blanco, Giuseppina

AU - Caputo, Giuseppe

AU - Bilancia, Domenico

AU - Bordonaro, Roberto

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Patients older than 75 years of age are usually excluded from metastatic colorectal cancer studies based on a combination chemotherapy containing oxaliplatin. Our group conducted three phase II trials in elderly patients in recent years. A post-hoc subgroup analysis of 67 patients aged at least 75 years was included in this study. Oxaliplatin was combined with capecitabine in two trials and with uracil-tegafur (UFT) plus folinic acid in the third trial. In one study, bevacizumab was also added to chemotherapy. The median age of patients was 77 years, and all had a good performance status (0 to 1). The observed overall response rate was 45%, comparable to younger patients (51%, p = 0.49). The estimated median progression-free survival (PFS) time and overall survival (OS) time were 8.7 and 19.3 months, respectively. These results did not significantly differ from those in younger patients (8.0 months for PFS (p = 0.58) and 19.7 months for OS (p = 0.94), respectively). The most common grade 3–4 adverse events included diarrhea (13%), fatigue (13%), peripheral neuropathy (10%), and neutropenia (7%). Moreover, the toxicity was never statistically different from that in younger patients. The efficacy of oxaliplatin-based combination was maintained in fit elderly patients ≥75 years.

AB - Patients older than 75 years of age are usually excluded from metastatic colorectal cancer studies based on a combination chemotherapy containing oxaliplatin. Our group conducted three phase II trials in elderly patients in recent years. A post-hoc subgroup analysis of 67 patients aged at least 75 years was included in this study. Oxaliplatin was combined with capecitabine in two trials and with uracil-tegafur (UFT) plus folinic acid in the third trial. In one study, bevacizumab was also added to chemotherapy. The median age of patients was 77 years, and all had a good performance status (0 to 1). The observed overall response rate was 45%, comparable to younger patients (51%, p = 0.49). The estimated median progression-free survival (PFS) time and overall survival (OS) time were 8.7 and 19.3 months, respectively. These results did not significantly differ from those in younger patients (8.0 months for PFS (p = 0.58) and 19.7 months for OS (p = 0.94), respectively). The most common grade 3–4 adverse events included diarrhea (13%), fatigue (13%), peripheral neuropathy (10%), and neutropenia (7%). Moreover, the toxicity was never statistically different from that in younger patients. The efficacy of oxaliplatin-based combination was maintained in fit elderly patients ≥75 years.

KW - Colorectal cancer

KW - Doublet chemotherapy

KW - Elderly patients

KW - Oxaliplatin

UR - http://www.scopus.com/inward/record.url?scp=85065424369&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065424369&partnerID=8YFLogxK

U2 - 10.3390/cancers11040578

DO - 10.3390/cancers11040578

M3 - Article

AN - SCOPUS:85065424369

VL - 11

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 4

M1 - 578

ER -